Overview
Xovoltib contains Afatinib Dimaleate, a targeted cancer therapy classified as a tyrosine kinase inhibitor. It is primarily used to treat non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR) gene.





